January 2024

Drs. Aguilera and Elghonaimy named part of TMCi's 2024 Accelerator for Cancer Therapeutics cohort

Texas Medical Center Innovation (TMCi) has named Drs. Todd Aguilera and Eslam Elghonaimy as part of their 2024 Accelerator for Cancer Therapeutics cohort, which recognizes health tech innovators working on promising cancer therapeutics.

TMCi news release

August 2023

Dr. Aguilera received White House-sponsored Cancer Moonshot award

Dr. Aguilera has been named one of 11 inaugural Cancer Moonshot Scholars. The national program recognizes a cohort of early-career investigators from underrepresented groups who have been identified as emerging leaders in cancer research and innovation.

White House Press Release

June 2020

Dr. Aguilera received Damon Runyon Award to study emerging immunotherapy

The Damon Runyon Cancer Research Foundation named Dr. Aguilera as one of four new Damon Runyon Clinical Investigators. The three-year, $600,000 award supports outstanding early career physician-scientists conducting patient-oriented cancer research with the potential to impact cancer diagnosis, prevention, and treatment.

Center Times

July 2021

Dr. Aguilera awarded SCCC Translational Pilot Award

Dr. Todd Aguilera, member of the Experimental Therapeutics Research Program, along with a multi-PI team, Andrew Jamieson, Ph.D., Assistant Professor of Bioinformatics; Ravikanth Maddipati, M.D., Assistant Professor of Internal Medicine, and Megan Wachsmann, M.D., Assistant Professor of Pathology, were awarded a SCCC Translational Pilot Award for “Interrogation of the Therapeutic Response in Pancreatic Adenocarcinoma to Identify Opportunities to Target the Tumor Immune Microenvironment.”

August 2017

Dr. Aguilera received the "CPRIT Recruitment of First-Time, Tenure-Track Faculty Member Award" for $2 million

Read about UTSW CPRIT Awards